02:57 PM EST, 11/12/2024 (MT Newswires) -- GSK (GSK) said Tuesday Health Canada has approved its blood cancer treatment Ojjaara for use in adults with intermediate or high-risk primary myelofibrosis.

The treatment is used for splenomegaly and other symptoms linked to myelofibrosis in patients, following polycythemia vera or essential thrombocythemia, who suffer from moderate to severe anemia, the company said.

Price: 35.57, Change: -0.79, Percent Change: -2.16